The Centers for Medicare & Medicaid Services (CMS) recently issued the State Medicaid and Children’s Health Insurance Program (CHIP) Applied Behavior Analysis (ABA) Toolkit, a comprehensive resource designed to help state Medicaid and CHIP agencies evaluate ABA service provision and policies for children with autism spectrum disorder (ASD). The Toolkit addresses several key issues facing ABA providers and investors, including expenditure growth, medical necessity, documentation, provider oversight, referral relationships and program integrity.
Why the Toolkit matters
The Toolkit reflects CMS's growing concern that ABA oversight is not keeping pace with the rapid growth of Medicaid-funded ABA services. CMS reports that Medicaid and CHIP spending on ABA services increased 421 percent between 2021 and 2025, while the number of beneficiaries with ASD diagnosis receiving ABA services increased 189 percent. The Toolkit follows a series of HHS-OIG audits of state Medicaid ABA spending, Department of Justice enforcement actions and government-wide oversight initiatives focused on provider enrollment, documentation, medical necessity and fraud prevention. Importantly, the Toolkit does not create new federal requirements. Instead, it provides a detailed roadmap of the operational, clinical and compliance issues CMS believes warrant closer oversight from states, providers, managed care organizations and investors.
The Toolkit is framed as guidance rather than regulation, and CMS is explicit that it does not establish a standard of care or direct clinical judgment. Nevertheless, it arrives at a moment of sustained federal focus on Medicaid program integrity at a global level and provides a detailed roadmap of the issues most likely to attract regulatory, audit and reimbursement scrutiny from both public and private payors. The Toolkit underscores the ongoing importance of robust compliance programs in sustaining day-to-day operations and preserving enterprise value.
As states navigate broader Medicaid financing and operational changes, the Toolkit may influence future state policy decisions even without new federal mandates. For providers and investors, the practical implications may emerge not only through federal enforcement activity, but also through state-level changes affecting reimbursement, authorization requirements and administrative oversight.
What the Toolkit signals
The Toolkit does not create new compliance obligations, as many of its recommendations are already grounded in existing federal and state oversight requirements. What it does signal, with considerable specificity, is which practices are likely to receive the most scrutiny and what CMS views as “best practices” for ABA operations and oversight.
CMS identified concerns with higher-intensity ABA and reaffirms the importance of individualized treatment plans tailored to a child’s therapeutic needs
The Toolkit makes clear at several points that 40 hours per week of ABA “is not a best practice” and raises concerns that higher-intensity ABA should not be authorized by default. CMS specifically notes that very high-intensity schedules may leave little time for schooling, family time and activities of daily living. The Toolkit also encourages states and managed care plans to consider policies that prohibit extended units of service without breaks, including requiring documentation of breaks for activities of daily living that are not reimbursable.
At several points, the Toolkit recommends increased oversight of each child’s individualized treatment plan to ensure treatment is narrowly tailored to individual needs. Common flags identified by CMS include:
- Overlapping treatments
- Lack of adaptation of an individualized treatment plan for personal needs
- Excessive service hours, or excessive service hours that continue without documented improvement in outcomes
- Identical documentation across individuals
- Reevaluations that do not reflect progress without adjustments
- High staffing ratios without clinical justification
- Lack of patient/caregiver engagement in the treatment process
The intensity of ABA treatment has become an increasing focus of payors in audit activity and investors in due diligence in recent years. The Toolkit offers another reminder that documentation should reflect an individualized assessment of each child’s therapeutic plan of care, with ongoing revisions based on the child’s needs and progress.
CMS reaffirmed that state Medicaid programs should focus on core program integrity responsibilities such as provider enrollment and regulation of referral relationships
The Toolkit addresses several ways for state Medicaid programs to strengthen oversight using existing or new authority. Provider enrollment was a particular area of focus, with CMS recommending that ownership changes and revalidations could be used as indicators for additional oversight.
State Medicaid programs are already required to enroll, screen and revalidate ABA providers on an ongoing basis, but the Toolkit emphasizes the change-of-ownership process and encourages states to focus on the provider’s organizational structure by requiring disclosure of organizational charts, operating agreements and management contracts. CMS also noted “[o]wnership transitions can lead to rapid growth, staff turnover and reduced supervision” and advises state agencies to “monitor staffing ratios, caseload growth and continuity of supervision” following an ownership change. Together, these recommendations suggest that acquisitions reported through the provider enrollment process may receive enhanced scrutiny, informed in part by changes reflected in the provider’s claims data following the transaction.
CMS also focused on state Medicaid oversight of referral relationships by encouraging states to consider enacting laws or coverage policies that are influenced by Stark Law principles with respect to financial relationships between diagnosing providers and ABA providers. The Toolkit identifies disclosure of financial or ownership relationships, prohibitions on compensation tied to referral volume and monitoring of referral and diagnosis patterns as tools states may use to address program integrity concerns.
CMS expressed skepticism towards telehealth enabled models
The Toolkit addresses telehealth-enabled delivery at several points and cautions that telehealth should not be used as the primary modality for ASD diagnosis or initial comprehensive assessments. Consistent with that position, CMS states that “Diagnostic and treatment authorization visits should occur in person.”
The Toolkit also notes that telehealth should be limited for direct Registered Behavior Technician (RBT)-delivered services, and should not substitute for in-person engagement where treatment fidelity, safety or attendance verification are at issue.
CMS encouraged state Medicaid plans, managed care organizations and ABA providers to move toward standardized outcomes measurement to support reassessment of treatment plans and value-based care reimbursement models
The Toolkit recommends that states require providers to perform at least one standardized outcome assessment instrument throughout the treatment course, not merely at intake, and states that provider-created outcome measures should not be used as the basis for documenting treatment progress or for the reauthorization of services. This recommendation may affect providers that rely on internal tools to support authorization or reauthorization of ABA rather than standardized outcomes measurement tools.
Standardizing quality and outcomes measurement in ABA therapy remains a significant topic of discussion among industry participants that goes beyond reassessing treatment plans and reauthorizing services. As payment models in physical medicine continue moving toward risk-sharing in value-based care arrangement, the ABA industry has not yet identified and operationalized a core set of outcomes measures that can be adopted broadly for use in value-based care models.
The Toolkit’s recommendation may push state Medicaid programs and ABA industry participants further toward implementing standardized outcomes measures that could serve as the building blocks for more widely implemented value-based care models by Medicaid programs and commercial payors.
Implications for transactions and immediate concerns
The Toolkit flags rapid growth and staff turnover as patterns that may warrant closer review of staffing ratios, caseloads and supervision. For platform strategies, rapid acquisitions, geographic expansion and headcount growth may attract additional scrutiny.
Diligence should address not only known retrospective risks, such as audit and recoupment activity, but also prospectively focus on a target’s current practices related to treatment intensity, authorizations, enrollment and credentialing compliance, outcome measurement, telehealth utilization and encounter data accuracy. These areas should be evaluated to determine whether the target’s practices may lead to regulatory scrutiny under factors identified in the Toolkit or state-specific coverage policies.
For transactions involving ABA providers, one of the most important compliance questions continues to be whether the target’s compliance infrastructure is operational rather than nominal. Policies, monitoring, internal audits, documentation review, credentialing controls and audit response capabilities should exist in practice, not just in binders. In the current environment, that distinction is increasingly relevant to audit risk, reimbursement stability and enterprise value.
Conclusion
The Toolkit rewards careful reading. Its recommendations are detailed and its publication coincides with an enforcement environment that has moved from monitoring to action, including prosecutions, payment deferrals and federal pressure on states to accelerate Medicaid provider revalidation.
The Toolkit is also candid about the concerns driving the scrutiny: rapid growth in spending and utilization, high-hour service patterns, inconsistent supervision models, insufficient documentation, variable outcome measurement and the risk that growth incentives sometimes outpace clinical and program integrity safeguards.
That candor is the point. CMS is signaling that Medicaid-funded growth in autism services must be supported by individualized treatment planning, measurable outcomes, appropriate supervision, accurate documentation and effective program integrity controls.
Providers and investors should treat the Toolkit for what it is: a detailed federal statement of where CMS believes ABA programs require closer oversight and where audit, reimbursement and enforcement attention are likely to follow.